Comparative in Vitro Activities of Nemonoxacin (TG-873870), a Novel Nonfluorinated Quinolone, and Other Quinolones Against Clinical Isolates

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2010 Jan 13

PMID 20065058

Citations 30

Authors

Tsai-Ling Lauderdale

Yih-Ru Shiau

Jui-Fen Lai

Hua-Chien Chen

Chi-Hsin R King

Affiliations

Soon will be listed here.

Abstract

The in vitro antibacterial activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, against 770 clinical isolates were investigated. Nemonoxacin (tested as its malate salt, TG-875649) showed better in vitro activity than ciprofloxacin and levofloxacin against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenzae. The in vitro activity of TG-875649 was also comparable to or better than that of moxifloxacin against these pathogens, which included ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus and levofloxacin-resistant Streptococcus pneumoniae.

Citing Articles

Comparative In vitro antibacterial activity of nemonoxacin and other fluoroquinolones in correlation with resistant mechanisms in contemporary methicillin-resistant Staphylococcus aureus blood isolates in Taiwan.

Chen P, Ho M, Lu P, Tang H, Sy C, Wang J Ann Clin Microbiol Antimicrob. 2025; 24(1):5.

PMID: 39825371 PMC: 11742215. DOI: 10.1186/s12941-024-00772-6.

Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease.

Meng W, Zeng H, Zhao Z, Xiong R, Chen Y, Li Z Sci Rep. 2023; 13(1):16954.

PMID: 37805617 PMC: 10560244. DOI: 10.1038/s41598-023-44188-2.

Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance.

Yuan J, Zhang X, Chen J, Zhang Y, Zhu F, Huang H Front Pharmacol. 2022; 13:1067686.

PMID: 36569296 PMC: 9780658. DOI: 10.3389/fphar.2022.1067686.

Nemonoxacin Enhances Antibacterial Activity and Anti-Resistance Mutation Ability of Vancomycin against Methicillin-Resistant Staphylococcus aureus in an Dynamic Pharmacokinetic/Pharmacodynamic Model.

Huang J, Guo S, Li X, Yuan F, Li Y, Xu B Antimicrob Agents Chemother. 2021; 66(2):e0180021.

PMID: 34902266 PMC: 8846321. DOI: 10.1128/AAC.01800-21.

Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.

Millanao A, Mora A, Villagra N, Bucarey S, Hidalgo A Molecules. 2021; 26(23).

PMID: 34885734 PMC: 8658791. DOI: 10.3390/molecules26237153.

References

Levy S, Marshall B . Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004; 10(12 Suppl):S122-9. DOI: 10.1038/nm1145. View

Yan J, Hsueh P, Lu J, Chang F, Shyr J, Wan J . Extended-spectrum beta-lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan. Antimicrob Agents Chemother. 2006; 50(5):1861-4. PMC: 1472213. DOI: 10.1128/AAC.50.5.1861-1864.2006. View

Lauderdale T, McDonald L, Shiau Y, Chen P, Wang H, Lai J . The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. Diagn Microbiol Infect Dis. 2004; 48(3):211-9. DOI: 10.1016/j.diagmicrobio.2003.10.005. View

McDonald L, Lauderdale T, Shiau Y, Chen P, Lai J, Wang H . The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme, 2000. Int J Antimicrob Agents. 2004; 23(4):362-70. DOI: 10.1016/j.ijantimicag.2003.09.021. View

Ma L, Lin C, Chen J, Fung C, Chang F, Lai Y . Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2008; 53(1):104-11. PMC: 2612171. DOI: 10.1128/AAC.00852-08. View